Table 2.
Microencapsulation formulations of l-Carnitine base using emulsion solvent evaporation method.
| Trial No. | Polymer Viscosity grade | Drug/Polymer Ratio | Anti-coalescent | mixing speed | Span 80 (%) |
|---|---|---|---|---|---|
| F1 | EC N100 | 3:1 | – | 500 | 0.1 |
| F2 | EC N100 | 3:1 | Aerosil 200 | 500 | 0.1 |
| F3 | EC N100 | 3:1 | Mg stearate | 500 | 0.1 |
| F4 | EC N100 | 3:1 | Aerosil 200 | 1000 | 0.1 |
| F5 | EC N100 | 3:1 | Aerosil 200 | 1500 | 0.1 |
| F6 | EC N100 | 3:1 | Aerosil 200 | 1000 | – |
| F7 | EC N100 | 3:1 | Aerosil 200 | 1000 | 0.25 |
| F8 | EC N100 | 3:1 | Aerosil 200 | 1000 | 0.5 |
| F9 | EC N100 | 3:1 | Aerosil 200 | 1000 | 1 |
| F10 | EC N100 | 4:1 | Aerosil 200 | 1000 | 0.1 |
| F11 | EC N100 | 2:1 | Aerosil 200 | 1000 | 0.1 |
| F12 | EC N100 | 1:1 | Aerosil 200 | 1000 | 0.1 |
| F13 | Ethocel Std. 20 | 4:1 | Aerosil 200 | 1000 | 0.1 |
| F14 | Ethocel Std. 20 | 3:1 | Aerosil 200 | 1000 | 0.1 |
| F15 | Ethocel Std. 20 | 2:1 | Aerosil 200 | 1000 | 0.1 |
| F16 | Ethocel Std. 20 | 1:1 | Aerosil 200 | 1000 | 0.1 |
F1, F2, and F3 represented the study of the Anti-coalescent type factor. From that stage, F2 succeeded to continue. F2, F4, and F5 demonstrated the mixing speed variable in the second-stage, from which F4 showed superiority. The study of the effect of emulsifier concentration (on F4, F6, F7, F8, and F9) in the third stage resulted in the choice of F4.